Biostar Pharmaceuticals EBIT

The latest EBIT for BSPM is $3.6M as of September 2017. That compares with $-30M in the prior-year period — up 111.7% year over year. That is above the sector sector average of $-27M. Investors often review this figure alongside Biostar Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, BSPM's EBIT moved from $-30M to $3.6M — a 111.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biostar Pharmaceuticals's operating scale or balance-sheet position.

Against its sector companies, BSPM currently prints $3.6M for EBIT, while the sector average sits near $-27M. That is roughly 113.2% above the sector mean. Large gaps often invite a closer look at Biostar Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $3.6M for BSPM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-27M. Explore the charts below for those layers of context.

After noting BSPM's EBIT ($3.6M), review year-over-year change from $-30M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.